Showing results (411-420 of 4,499) with videos related to

Sort By:
Pageof 450
Advances in Therapy|September 11, 2024
Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02Ana Oaknin, Jung-Yun Lee, Vicky Makker, et al.
Advances in Therapy|March 2, 2025
Patient-Reported Outcomes for Patients with Previously Treated Small Cell Lung Cancer Receiving Tarlatamab: Results from the DeLLphi-301 Phase 2 TrialHorst-Dieter Hummel, Myung-Ju Ahn, Fiona Blackhall, et al.
Advances in Therapy|March 2, 2025
First-Line Pembrolizumab Plus Chemotherapy for HER2-Negative Advanced Gastric Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-859 StudyShukui Qin, Yuxian Bai, Jin Li, et al.
Advances in Therapy|February 27, 2025
Patient and Health Care Professional Perspectives on the Burden and Daily Life Impact of Ulcerative Colitis and Crohn's Disease: Results from the Japanese CONFIDE StudyToshifumi Hibi, Taku Kobayashi, Masaru Tanaka, et al.
Advances in Therapy|February 19, 2025
Onset and Long-Term Maintenance of Optimal Itch Response in Adult Patients with Moderate-to-Severe Atopic Dermatitis Treated with Dupilumab: Post Hoc Analysis from Two Phase 3 TrialsSonja Ständer, Gil Yosipovitch, Eric L Simpson, et al.
Advances in Therapy|August 31, 2024
Real-World Effectiveness of Mepolizumab in Severe Asthma: Results from the Multi-country, Self-controlled Nucala Effectiveness Study (NEST)Riyad Omar Al-Lehebi, Mona Al Ahmad, Venkata Nagarjuna Maturu, et al.
Advances in Therapy|August 10, 2024
Comparative Efficacy and Safety of Upadacitinib vs. Vedolizumab, Ustekinumab, and Tofacitinib After Induction and Maintenance for Ulcerative Colitis: Three Matching-Adjusted Indirect ComparisonsWalter Reinisch, Gil Y Melmed, Hiroshi Nakase, et al.
Advances in Therapy|August 14, 2024
Real-World Treatment Persistence Among Advanced Therapy-Naïve or -Experienced Patients with Ulcerative Colitis Initiated on Ustekinumab or AdalimumabMaryia Zhdanava, Sumesh Kachroo, Porpong Boonmak, et al.
Advances in Therapy|August 14, 2024
The Broader Effects of Delayed Progression to End-Stage Kidney Disease: Delaying the Inevitable or a Meaningful Change?Ricardo Correa-Rotter, David C Wheeler, Phil McEwan
Advances in Therapy|August 14, 2024
Adherence, Persistence, Healthcare Resource Use, and Costs in Tofacitinib-Treated Patients with Psoriatic Arthritis: Data from Two United States Claims DatabasesPhilip J Mease, Eros Papademetriou, Ravi Potluri, et al.
Pageof 450